Sandoz Canada launch a brand new multi-platform application, which allows healthcare professionals to have this crucial information at their fingertips. Sandoz Pro app (sandozpro.sandoz.ca) allows users to view information on availability of injectable medicines. This new tool is designed for healthcare professionals and buyers who want to make the most of their time, as it helps them plan their injectable drug supplies and make informed decisions at all times.
Sandoz, a Novartis company and the global leader in biosimilars, announced that US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen's US-licensed Enbrel (etanercept) - a tumour necrosis factor alpha (TNF-alpha) inhibitor. This is the second BLA submission by Sandoz using the 351(k) biosimilar pathway.
Sandoz, a Novartis company and a global leader in generic pharmaceuticals launch of first biosimilar Zarxio (filgrastim-sndz). Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA).
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
